3 In PARAGON-HF, which enrolled patients with HF and preserved ejection fraction, sacubitril/valsartan narrowly missed statistical significance for its primary end point. 4 However, a subgroup analysis suggested potential benefits in subjects with below-normal left ventricular ejection fraction.
← all excerpts
Heart Failure Guideline-Directed Medical Therapy in End-Stage Kidney Disease: From PARADIGM-HF to Clinical Practice.
1
—
—